英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
shareholders查看　shareholders　在百度字典中的解释百度英翻中〔查看〕
shareholders查看　shareholders　在Google字典中的解释Google英翻中〔查看〕
shareholders查看　shareholders　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Diagnosis and Treatment of ALK Positive NSCLC - PMC
    Anaplastic lymphoma kinase (ALK) gene rearrangements occur in a small portion of patients with non-small cell lung cancer (NSCLC) These gene rearrangements lead to constitutive activation of the ALK kinase and subsequent ALK driven tumor formation
  • Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
    Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
  • ALK+ NSCLC Treatment Guidelines
    Use of ALK TKIs is effective for treatment of patients with ALK+ NSCLC and CNS involvement, and evidence supports alectinib, brigatinib or ceritinib in this setting as first-line therapy
  • Lorbrena Effective as Initial Treatment of ALK-Positive NSCLC
    Lorlatinib (Lorbrena) was superior to crizotinib (Xalkori) as an initial treatment for advanced ALK-positive non-small cell lung cancer, trial results show
  • Real-World Treatment and Outcomes in ALK-Rearranged NSCLC . . .
    ALK–rearranged advanced NSCLC (aNSCLC) represents 4% of all NSCLCs, and multiple ALK-targeted therapies (ALK-inhibitors) are now available for use Little is known about changes in treatment patterns, or how prognostic factors and sequence of therapy may impact overall survival in the real-world setting We aim to describe initial and subsequent treatments used, survival outcomes, prognostic
  • Anaplastic lymphoma kinase (ALK)-positive advanced non-small . . .
    The molecular pathogenesis, clinical features, and treatment of NSCLC associated with the ALK fusion oncogene are discussed here An overview of the treatment of metastatic NSCLC, ALK-positive early NSCLC, and the methods and indications for molecular testing are presented elsewhere
  • Real-world treatment sequencing and effectiveness of second . . .
    With multiple targeted therapies approved for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), it is increasingly important to understand outcomes with various sequences of next-generation ALK tyrosine kinase inhibitors (TKIs) We describe contemporary sequencing patterns and treatment effectiveness of first-line (1L) and second-line (2L) treatments in
  • Evaluating Diagnostic and Treatment Timelines for ALK . . .
    MicroabstractThe ALK Life Study analyzed diagnostic and treatment timelines in 1288 ALK-positive NSCLC patients from 71 countries The median time to diagnosis was 45 days, and time to TKI treatment was 30 days for advanced-stage patients Younger age, comorbidities, and geographic factors were linked to delays Outcomes may be improved by raising awareness amongst clinicians of the frequency
  • FDA approves alectinib as adjuvant treatment for ALK-positive . . .
    On April 18, 2024, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc ) for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK
  • Targeting ALK Rearrangements in NSCLC: Current State of the Art
    Recently, a potent, third-generation ALK inhibitor, lorlatinib, has been approved by the Food and Drug Administration (FDA) for the first-line treatment of ALK-positive (ALK+) NSCLC These drugs have manageable toxicity profiles





中文字典-英文字典  2005-2009